Anti-invasive effects and proapoptotic activity induction by the rexinoid IIF and valproic acid in combination on colon cancer cell lines

Anticancer Research

Volumn 32, Issue 7, 2012, Pages 2855-2862

  Papi, A ^a   Ferreri, Anna Maria ^a   Guerra, F ^a   Orlandi, M ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Anti invasive effects; Apoptosis; Colon cancer cell lines; Histone deacetylase inhibitors; IIF; Matrix metalloproteinases; Rexinoid; Valproic acid

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 9; GELATINASE A; GELATINASE B; METALLOPROTEINASE INHIBITOR; PROTEIN BCL 2; RETINOID X RECEPTOR; REXINOID 6 OH 11 O HYDROXYPHENANTHRENE; TIMP1 PROTEIN; TIMP2 PROTEIN; UNCLASSIFIED DRUG; VALPROIC ACID;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; COLON CANCER; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CASPASE 3; CASPASE 9; COLONIC NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; HISTONE DEACETYLASE INHIBITORS; HT29 CELLS; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; NEOPLASM INVASIVENESS; RETINOID X RECEPTOR GAMMA; TRETINOIN; VALPROIC ACID;

EID: 84865679694     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Stumpf CR and Ruggero D: The cancerous translation apparatus. Curr Opin Genet Dev 21(4): 474-483, 2011.
2. Silvera D, Formenti SC and Schneider RJ: Translational control in cancer. Nat Rev Cancer 10(4): 254-266, 2010.
3. Seidel C, Schnekenburger M, Dicato M and Diederich M: Histone deacetylase modulators provided by Mother Nature. Genes Nutr 1: 1-10, 2012.
4. Peng L and Seto E: Deacetylation of nonhistone proteins by HDACs and the implications in cancer. Handb Exp Pharmacol 206: 39-56, 2011.
5. Rahman R and Grundy R: Histone deacetylase inhibition as an anticancer telomerase-targeting strategy. Int J Cancer 129(12): 2765-2774, 2011.
6. Liu T, Kuljaca S, Tee A and Marshall GM: Histone deacetylase inhibitors: multifunctional anticancer agents. Cancer Treat Rev 32(3): 157-165, 2006.
7. Ellis L and Pili R: Histone deacetylase inhibitors: advancing therapeutic strategies in hematological and solid malignancies. Pharmaceuticals (Basel) 3(8): 2411-2469, 2010.
8. Marson CM: Histone deacetylase inhibitors: design, structure, activity relationship and therapeutic implications for cancer. Anticancer Agents Med Chem 9: 661-692, 2009.
9. Papi A, Ferreri AM, Rocchi P, Guerra F and Orlandi M: Epigenetic modifiers as anticancer drugs: Effectiveness of valproic acid in neural crest-derived tumor cells. Anticancer Res 30(2): 535-540, 2010.
10. De los Santos M, Zambrano A and Aranda A: Combined effects of retinoic acid and histone deacetylase inhibitors on human neuroblastoma SH-SY5Y cells. Mol Cancer Ther 6(4): 1425-1432, 2007.
11. Bartolini G, Orlandi M, Papi A, Ammar K, Tonelli R, Franzoni M, Pession A, Rocchi P and Ferreri AM: Growth inhibition and proapoptotic activity induction by IIF and Valproic acid on RA-resistant leukemia cells. Anticancer Res 28(1): 283-288, 2008.
12. Tang XH and Gudas LJ: Retinoids, retinoic acid receptors, and cancer. Annu Rev Pathol 6: 345-364, 2011.
13. Szanto A, Narkar V, Shen Q, Uray IP, Davies P and Nagy L: Retinoid X receptors: X-ploring their (patho)physiological functions. Cell Death Differ 11: S126-S143, 2004.
14. Germain P, Chambon P, Eichele G, Evans RM and Lazar MA: Retinoid X receptors. Pharmacol Rev 58: 760-772, 2006.
15. Peters JM, Shah YM and Gonzalez FJ: The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention. Nat Rev Cancer 12(3): 181-195, 2012.
16. Bartolini G, Orlandi M, Papi A, Ammar A, Guerra A, Ferreri AM and Rocchi P: Search for multidrug resistance modulators: effects of retinoids in human colon carcinoma cells. In Vivo 20: 729-733, 2006.
17. Papi A, Bartolini G, Ammar K, Guerra G, Ferreri AM, Rocchi P and Orlandi M: Inhibitory effects of retinoic acid and 6-OH-11-O-hydroxyphenanthrene on growth, migration and invasiveness in U87MG human glioblastoma cell line. Oncology Rep 18(4): 1015-1021, 2007.
18. Dozza B, Papi A, Lucarelli E, Scotlandi K, Pierini M, Tresca G, Donati D and Orlandi M: Cell growth inhibition and apoptotic effect of the rexinoid 6-OH-11-O-hydroxyphenanthrene on human osteosarcoma and mesenchymal stem cells. Toxicol In Vitro 26(1): 142-149, 2012.
19. Papi A, Guarnieri T, Storci G, Santini D, Ceccarelli C, Taffurelli M, De Carolis S, Avenia N, Sanguinetti A, Sidoni A, Orlandi M and Bonafé M: Nuclear receptors agonists exert opposing effects on the inflammation dependent survival of breast cancer stem cells. Cell Death Differ 1: 1-12, 2012.
20. Papi A, Rocchi P, Ferreri AM, Guerra F and Orlandi M: Enhanced effects of PPARγ ligands and RXR selective retinoids in combination to inhibit migration and invasiveness in cancer cells. Oncology Rep 21(4): 1083-1089, 2009.
21. Papi A, Rocchi P, Ferreri AM and Orlandi M: RXRγ and PPARγ ligands in combination to inhibit proliferation and invasiveness in colon cancer cells. Cancer Let 297: 65-74, 2010.
22. Papi A, Tatenhorst L, Terwel D, Hermes M, Kummer M.P, Orlandi M. and Heneka M: PPARγ and RXR ligand act sinergistically as potent antineoplastic agents in vitro and in vivo glioma models. J Neurochem 109: 1779-1790, 2009.
23. Luu T, Chung C and Somlo G: Combining emerging agents in advanced breast cancer. Oncologist 16(6): 760-771, 2011.
24. Zoli W, Ricotti L, Tesei A, Barzanti F and Amadori D: In vitro preclinical models for a rational design of chemotherapy combinations in human tumors. Crit Rev Oncol Hematol 37: 69-82, 2001.
25. Köhler C, Orrenius S and Zhivotovsky B: Evaluation of caspase activity in apoptotic cells. J Immunol Methods 265: 97-110, 2002.
26. Mariadason JM: HDACs and HDAC inhibitors in colon cancer. Epigenetics 3(1): 28-37, 2008.
27. Sandor V, Bakke S, Robey RW, Kang MH, Blagosklonny MV, Bender J, Brooks R, Piekarz RL, Tucker E, Figg WD, Chan KK, Goldspiel B, Fojo AT, Balcerzak SP and Bates SE: Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 8: 718-728, 2002.
28. Bruserud O, Stapnes C, Ersvaer E, Gjertsen BT and Ryningen A: Histone deacetylase inhibitors in cancer treatment: a review of the clinical toxicity and the modulation of gene expression in cancer cells. Curr Pharm Biotechnol 8: 388-400, 2007.
29. Eisinger AL, Nadauld LD, Shelton DN, Prescott SM, Stafforini DM and Jones DA: Retinoic acid inhibits beta-catenin through suppression of COX2: a role for truncated adenomatous polyposis coli. Biol Chem 282(40): 29394-29400, 2007.
30. Kong G, Kim HT, Wu K, De Nardo D, Hilsenbeck SG, Xu XC, Lamph WW, Bissonnette R, Dannenberg AJ and Brown PH: The retinoid X receptor-selective retinoid, LGD1069, down-regulates cyclooxygenase-2 expression in human breast cells through transcription factor crosstalk: implications for molecular-based chemoprevention. Cancer Res 65(8): 3462-3469, 2005.
31. Angelucci A, Muzi P, Cristiano L, Millimaggi D, Cimini A, Dolo V, Miano R, Vicentini C, Cerù MP and Bologna M: Neuroendocrine transdifferentiation induced by VPA is mediated by PPARgamma activation and confers resistance to antiblastic therapy in prostate carcinoma. Prostate 68(6): 588-598, 2008.
32. Chen X, Wong P, Radany E and Wong JY: HDAC inhibitor, valproic acid, induces p53-dependent radiosensitization of colon cancer cells. Cancer Biother Radiopharm 24: 689-699, 2009.
33. Jones J, Bentas W, Blaheta RA, Makarevic J, Hudak L, Wedel S, Probst M, Jonas D and Juengel E: Modulation of adhesion and growth of colon and pancreatic cancer cells by the histone deacetylase inhibitor valproic acid. Int J Mol Med 22(3): 293-299, 2008.
34. Huang X and Guo B: Adenomatous polyposis coli determines sensitivity to histone deacetylase inhibitor-induced apoptosis in colon cancer cells. Cancer Res 66(18): 9245-9251, 2006.
35. Mottet D and Castronovo V: Histone deacetylases: target enzymes for cancer therapy. Clin Exp Metastasis 25: 183-189, 2008.